

Plasma Phospholipid Transfer Protein Activity Is Decreased in Type 2 Diabetes During Treatment With Atorvastatin

A Role for Apolipoprotein E?

Geesje M. Dallinga-Thie,¹ Arie van Tol,^{2,3} Hiroaki Hattori,⁴ Patrick C.N. Rensen,⁵ and Eric J.G. Sijbrands,¹ for the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group*

Plasma phospholipid transfer protein (PLTP) plays an important role in lipoprotein metabolism. PLTP activity is elevated in patients with diabetes, a condition with strongly elevated risk for coronary heart disease. The aim of this study was to test the hypothesis that statins reduce PLTP activity and to examine the potential role of apolipoprotein E (apoE). PLTP activity and apoE were measured in patients with type 2 diabetes from the DALI (Diabetes Atorvastatin Lipid Intervention) Study, a 30-week randomized double-blind placebo-controlled trial with atorvastatin (10 and 80 mg daily). At baseline, PLTP activity was positively correlated with waist circumference, HbA_{1c}, glucose, and apoE (all $P < 0.05$). Atorvastatin treatment resulted in decreased PLTP activity (10 mg atorvastatin: -8.3% , $P < 0.05$; 80 mg atorvastatin: -12.1% , $P < 0.002$). Plasma apoE decreased by 28 and 36%, respectively ($P < 0.001$). The decrease in apoE was strongly related to the decrease in PLTP activity ($r = 0.565$, $P < 0.001$). The change in apoE remained the sole determinant of the change in PLTP activity in a multivariate model. The activity of PLTP in type 2 diabetes is decreased by atorvastatin. The association between the decrease in PLTP activity and apoE during statin treatment supports the hypothesis that apoE may prevent PLTP inactivation. *Diabetes* 55:1491–1496, 2006

From the ¹Department of Internal Medicine, Vascular and Metabolic Diseases, Erasmus Medical Center, Rotterdam, the Netherlands; the ²Department of Cell Biology and Genetics, Erasmus Medical Center, Rotterdam, the Netherlands; the ³Department of Endocrinology and Metabolism, University Medical Center Groningen, Groningen, the Netherlands; ⁴Advanced Medical Technology and Development, BML, Saitama, Japan; and the ⁵Departments of General Internal Medicine, Endocrinology and Metabolism, Leiden University Medical Center, Leiden, the Netherlands.

Address correspondence and reprint requests to G.M. Dallinga-Thie, Department of Internal Medicine, Vascular and Metabolic Diseases, Bd 277, Erasmus Medical Center, Dr Molewaterplein 40, 3015GD Rotterdam, PO Box 2040, 3000 CA, Rotterdam, Netherlands. E-mail: g.dallinga@erasmusmc.nl.

Received for publication 27 December 2005 and accepted in revised form 6 February 2006.

*A complete list of DALI Study Group members can be found in the APPENDIX.

apo, apolipoprotein; DALI, Diabetes Atorvastatin Lipid Intervention; PLTP, phospholipid transfer protein.

DOI: 10.2337/db05-1685

© 2006 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Patients with type 2 diabetes have a severely increased risk for cardiovascular morbidity and mortality (1,2). An atherogenic lipoprotein profile, characterized by increased plasma levels of triglycerides, decreased levels of HDL cholesterol, and presence of small dense LDL particles, is a major determinant, although the exact underlying molecular mechanisms remain to be established (3). HDL plays a central role in lipoprotein metabolism. The process of reverse cholesterol transport, i.e., the transport of cholesterol from peripheral tissues to the liver for degradation and excretion, is mediated through HDL (4). Furthermore, HDL functions as an antioxidant and anti-inflammatory agent. All functions of HDL have a similar tenacity: they protect against the development of atherosclerosis. Thus, decreased levels of plasma HDL cholesterol as seen in type 2 diabetes are pro-atherogenic.

Plasma lipid transfer proteins have an important role in remodeling of HDL. Two major lipid transfer proteins are described: cholesterylester transfer protein and phospholipid transfer protein (PLTP) (5). Plasma PLTP resides on HDL particles and is involved in phospholipid transfer activity (6). In vitro, its activity results in HDL conversion, generating large HDL₂ and small pre- β HDL particles that participate in cellular cholesterol efflux (7,8). This action implies a potential antiatherogenic function of PLTP (9). In vivo studies in PLTP-deficient mice have illustrated the physiological importance of PLTP in transfer of surface fragments to HDL that originate from triglyceride-rich lipoproteins during lipolysis by the enzyme lipoprotein lipase (10–12). Furthermore, PLTP was shown to be involved in the hepatic secretion of apolipoprotein B (apoB)-containing lipoproteins (13,14). This may explain the decreased susceptibility for diet-induced atherosclerosis in PLTP-deficient mice (14). Studies with transgenic mice revealed increased atherogenesis (15–17). Thus, PLTP appears to be pro-atherogenic in vivo in mice. In line with these animal studies, a study in humans provided evidence for a positive association between PLTP activity and coronary artery disease (18).

Plasma PLTP activity levels are elevated in type 2 diabetes (19), type 1 diabetes (20), hypertriglyceridemia (21), obesity (22,23), and patients with systemic inflamma-

TABLE 1
Characteristics of the study cohort

Characteristics	Placebo	10 mg atorvastatin	80 mg atorvastatin
<i>n</i>	71	72	72
Age (years)	59 ± 8	60 ± 8	60 ± 8
BMI (kg/m ²)	32.2 ± 6.1	30.0 ± 3.8	30.4 ± 4.5
Waist (cm)	108 ± 16	106 ± 12	106 ± 14
A1C (%)	8.76 ± 1.25	8.67 ± 1.27	8.86 ± 1.22
Glucose (mmol/l)	10.6 ± 3.6	10.5 ± 3.1	10.6 ± 2.9
Cholesterol (mmol/l)	6.03 ± 0.88	5.94 ± 0.95	6.04 ± 0.90
Triglycerides (mmol/l)	2.76 ± 0.95	2.68 ± 0.91	2.99 ± 1.14
HDL cholesterol (mmol/l)	1.05 ± 0.21	1.05 ± 0.26	1.03 ± 0.24
ApoAI (g/l)	1.41 ± 0.19	1.39 ± 0.20	1.39 ± 0.21
ApoB (g/l)	1.24 ± 0.20	1.19 ± 0.20	1.23 ± 0.22

Data are the means ± SD.

tion (24). Recently, PLTP has also been implicated to play a role in lipid metabolism in the brain (25–28). Not all PLTP molecules in plasma are active because PLTP mass is present in two distinct forms, one active in phospholipid transfer and one inactive (29,30). These forms react differently to PLTP antibodies used in PLTP enzyme-linked immunosorbent assay, and they may explain the poor correlation between PLTP mass and PLTP activity (31). Data in the literature suggest a potential relationship between apoE and PLTP activity. The active form of PLTP copurifies with apoE (32). In addition, secretion of active PLTP and apoE from HepG2 cells are associated (33). Interestingly, in a recent *in vitro* study, it was shown that apoE is able to activate the low-activity form of PLTP, suggesting a role for apoE in the regulation of PLTP activity (34).

The effect of statins on PLTP has not been studied. We hypothesized that statins influence PLTP activity by a mechanism involving changes in the level of circulating mass of apoE. Therefore, we investigated the influence of atorvastatin on PLTP activity and mass and the relation with plasma apoE in patients with type 2 diabetes of the Diabetes Atorvastatin Lipid Intervention (DALI) study. The DALI study was a double-blind randomized placebo-

controlled trial comparing effects of atorvastatin 10 and 80 mg daily on plasma lipids and apos (35).

RESEARCH DESIGN AND METHODS

This study comprised 215 patients enrolled in the DALI study. DALI was a double-blind randomized placebo-controlled multicenter study evaluating the effect of 10 vs. 80 mg atorvastatin daily on lipid metabolism, endothelial function, coagulation, and inflammatory factors in unrelated men and women with type 2 diabetes. The protocol and eligibility criteria have been described in detail elsewhere (35). Briefly, men and women aged 45–75 years with duration of diabetes for at least 1 year and an HbA_{1c} (A1C) ≤ 10% were eligible. The diagnosis of type 2 diabetes was defined according to the American Diabetes Association classification (36). Lipid inclusion criteria were total cholesterol between 4.0 and 8.0 mmol/l and fasting triglycerides between 1.5 and 6.0 mmol/l. Patients were recruited in Leiden, Rotterdam, and Utrecht, the Netherlands. The ethical committees of the participating centers approved the study protocol, and written informed consent was obtained from all subjects. **Laboratory measurements.** After an overnight fast for a minimum of 12 h, blood was drawn into EDTA-containing tubes for analysis of lipid profiles at baseline and after treatment for 30 weeks. Plasma was prepared by immediate centrifugation (3,000g, 15 min, 4°C), and samples were stored at –80°C for further analyses. Cholesterol and triglycerides were determined by enzymatic colorimetric methods on a Hitachi 911 automatic analyzer (Boehringer Mannheim, Mannheim, Germany). ApoB and apoAI were assayed, using automated immunoturbidimetric assays (Tina-Quant; Roche Diagnostics, Mannheim, Germany). Plasma apoE was analyzed automatically with a nephelometric assay (Wako, Osaka, Japan). Plasma HDL cholesterol was

TABLE 2
Plasma PLTP mass and activity and apoE and apoAI levels before and after treatment

Variable	Baseline	Week 30	% change
PLTP mass (mg/l)			
Placebo	8.88 ± 2.57	8.83 ± 2.70	–0.6
10 mg atorvastatin	9.00 ± 3.28	9.26 ± 3.15	2.8*
80 mg atorvastatin	8.63 ± 3.11	9.63 ± 3.09	11.6†
PLTP activity (%)			
Placebo	106.7 ± 18.0	107.3 ± 18.8	0.9
10 mg atorvastatin	107.8 ± 18.3	99.7 ± 16.1	–8.3‡
80 mg atorvastatin	108.8 ± 21.8	96.8 ± 18.6	–12.1†
ApoE (mg/100 ml)			
Placebo	4.46 ± 0.80	4.52 ± 1.12	0.9
10 mg atorvastatin	4.34 ± 1.02	3.15 ± 0.83	–28†
80 mg atorvastatin	4.68 ± 1.17	2.99 ± 1.06	–36†
ApoAI (mg/100 ml)			
Placebo	141 ± 19	137 ± 18	–2.8
10 mg atorvastatin	139 ± 20	138 ± 20	–0.71
80 mg atorvastatin	139 ± 21	134 ± 20	–3.6

Data are the means ± SD, and PLTP activity is % of reference plasma. Placebo: *n* = 71; A10: *n* = 72; A80: *n* = 72. Test was for difference among the three groups, adjusted for baseline value. **P* < 0.003 A10 vs. A80; †*P* < 0.001 vs. placebo; ‡*P* < 0.01 vs. placebo.

TABLE 3
Plasma apoE and plasma PLTP activity levels per apoE genotype group

ApoE genotype	n	Plasma apoE (mg/100 ml)	Plasma PLTP activity
ApoE 2/3	34	5.24 ± 1.14	108.8 ± 17.8
ApoE 3/3	133	4.31 ± 0.85	108.0 ± 21.2
ApoE 2/4	6	5.18 ± 0.80	104.4 ± 11.1
ApoE 3/4	37	4.17 ± 0.92	106.2 ± 16.5
ApoE 4/4	4	4.53 ± 0.92	99.3 ± 12.2

Data are the means ± SD. Plasma PLTP activity is percent of reference plasma.

measured by a direct enzymatic method based on polyethylene glycol-modified enzymes, using a Hitachi 911 autoanalyzer (Roche Diagnostics). LDL cholesterol was estimated with the Friedewald formula (37). Fasting plasma glucose was determined on a Hitachi 917 analyzer using an UV-hexokinase method (catalog no. 18766899; Boehringer Mannheim). A1C was determined by high-pressure liquid chromatography, using the Variant method (catalog no. 270-0003; BioRad).

PLTP mass and activity. Plasma PLTP mass was analyzed as previously described (29). The between-assay coefficient of variation (CV) and within-assay CV were <3.5 and <2.8%, respectively. Plasma PLTP activity was measured in a liposome vesicles-HDL system as described previously (38,39). In short, plasma samples were incubated for 45 min, 37°C, with [¹⁴C]dipalmitoyl-phosphatidylcholine-labeled liposomes and an excess of HDL, followed by precipitation of the liposomes with a mixture of NaCl, MgCl₂, and heparin (final concentrations 230 mmol/l, 92 mmol/l, and 200 units/ml, respectively). The measured PLTP activities are linearly related to the amount of plasma used in the incubations (0.5–1.0 μl). The method is not influenced by the phospholipid transfer-promoting capacities of cholesterylester transfer protein (38). Plasma PLTP activity was related to the activity measured in a reference plasma pool, based on plasma collected from 200 randomly selected healthy individuals, and is expressed as the percentage of the activity measured in this reference plasma, which was included in every assay. The PLTP activity in this reference plasma was 21.2 μmol · ml⁻¹ · h⁻¹. The between- and within-assay CVs were 4.8 and 3.5%, respectively.

Statistical analysis. All data are expressed as the means ± SD. All statistical analyses were carried out with SPSS software (version 12.0). Mean differences between the groups were analyzed, using ANOVA. To analyze determinants of PLTP activity and PLTP mass, we used the following strategy. First, univariate linear regression analyses was performed in the total cohort with PLTP activity and PLTP mass as dependent variables and the determinant of interest as an independent variable. Second, multivariate regression analysis was performed with PLTP activity and PLTP mass as dependent outcome variables, sex and waist as confounders, and statistically significant variables as independent variables. Third, the effect of treatment on PLTP activity, PLTP mass, and apoE was analyzed with two-way ANCOVA, using a placebo-controlled setting. Throughout, a two-tailed *P* value of <0.05 was interpreted as indicating a statistically significant difference.

TABLE 4
Correlation between plasma PLTP activity and baseline parameters

Parameter	Effect (β)	<i>P</i> value
Age	-0.116	NS
Sex	0.033	NS
Waist*	0.243	<0.001
Glucose*	0.169	0.015
A1C*	0.169	0.014
ApoE*	0.208	0.004

*All analyses were performed using multiple linear regression analyses, adjusted for age and sex and each determinant separately. HDL cholesterol, apoAI, and triglycerides do not contribute significantly to the variation in PLTP activity.

RESULTS

The characteristics of the 215 patients have been extensively described (35) and are summarized in Table 1. The atherogenic lipoprotein profile of the patients was characterized by elevated plasma triglycerides (2.81 ± 1.01 mmol/l) and decreased plasma HDL cholesterol (1.04 ± 0.24 mmol/l) levels. The mean plasma cholesterol levels were 6.0 ± 0.9 mmol/l. Average A1C was 8.3 ± 1.1%, and plasma glucose was 10.6 ± 3.2 mmol/l. The average duration of diabetes was 10.5 years.

Baseline findings. Baseline plasma PLTP mass concentrations varied from 2.50 to 24.50 mg/l, with an average of 8.84 ± 3.01 mg/l, and were similar in the three treatment groups (Table 2). Plasma PLTP activity at baseline varied from 64.4 to 187.1%, with an average of 107.6 ± 19.4%, and was identical in the three treatment groups. The correlation between baseline plasma PLTP mass and activity was low (*r* = 0.120, NS). Baseline plasma apoE concentrations were 4.49 ± 1.02 mg per 100 ml. One important determinant for plasma apoE levels is the apoE genotype. In the present study cohort, the apoE genotypes were in Hardy-Weinberg equilibrium ($\chi^2 = 2.916$, degrees of freedom = 3, *P* = 0.4): 62% of the patients had the apoE3/E3 genotype, 17% apoE2/E3, 3% apoE2/E4, 17% apoE3/apoE4, and 1% apoE4/E4. The average apoE and PLTP activity levels per apoE genotype group are shown in Table 3. No significant effect of apoE genotype on PLTP activity was found.

Waist circumference, plasma glucose, A1C, and plasma apoE were associated with baseline PLTP activity (Table 4, Fig. 1). In multivariate analyses, adjusted for age and




FIG. 1. Relationship between plasma PLTP activity and plasma apoE levels at baseline. Spearman correlation coefficient $r_s = 0.21$, *P* < 0.05.


TABLE 5
Correlation between plasma PLTP mass and baseline parameters

Parameter	Effect (β)	<i>P</i> value
Age	0.269	0.001
Sex	0.144	0.044
Waist*	-0.017	NS
HDL cholesterol*	0.719	0.001
ApoAI*	0.594	0.001
ApoE*	-0.164	0.019
Triglycerides*	-0.395	0.001

*All analyses were performed using linear regression analyses, adjusted for age and sex and each determinant separately. A1C and glucose do not contribute significantly to the variation of PLTP mass.

sex, only waist circumference and plasma apoE remained major determinants of plasma PLTP activity. None of the other lipid (including cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) and apo (apoAI and apoB) parameters showed a significant correlation. Plasma PLTP mass is known to be predominantly determined by the levels of plasma HDL cholesterol and apoAI (21). In our analyses both HDL cholesterol and apoAI contributed to the variation of plasma PLTP mass, independent of age, sex, and waist circumference. Plasma apoE and triglyceride concentrations were less important determinants (Table 5).

Treatment with atorvastatin. As expected, adjusted for the placebo effect, treatment with atorvastatin resulted in a dose-dependent decrease in plasma total cholesterol, LDL cholesterol, and apoB (all $P < 0.001$) (35). Plasma HDL cholesterol increased by 6.0 and 5.2% with 10 and 80 mg atorvastatin, respectively ($P < 0.05$), whereas plasma apoAI levels remained unchanged (Table 2). Plasma PLTP activity decreased by 8.3% ($P < 0.01$) and 12.1% ($P < 0.001$), respectively. The difference between the two groups did not reach statistical significance, but the trend was significant ($P < 0.01$). In contrast, plasma PLTP mass increased by 2.8% (NS) and 11.6% ($P < 0.001$), respectively. The difference between 10 and 80 mg atorvastatin was significant ($P < 0.005$). Plasma apoE levels were strongly decreased after atorvastatin treatment by 28 and 36%, respectively (both $P < 0.001$ vs. control). In a multivariate placebo-controlled analyses, including all lipid and apo parameters, the decrease in PLTP activity was only predicted by the decrease in apoE (standardized coefficient $\beta = 0.529$, $P < 0.0001$) (Fig. 2). Similar results were obtained when only individuals with the apoE3/E3 genotype were analyzed ($n = 133$, $r = 0.513$, $P < 0.001$), illustrating that the effect is independent of the apoE genotype.



DISCUSSION

In patients with type 2 diabetes, we found that atorvastatin treatment resulted in a decrease in PLTP activity and an increase in PLTP mass, leading to a substantial change in mass-adjusted activity. Statistical analysis revealed that the change in apoE and the change in PLTP activity are associated, thereby supporting the concept that apoE may be essential for the stability of the PLTP protein and its activity.

It has been shown that patients with type 2 diabetes have increased levels of plasma PLTP activity (19,40). Positive associations have been reported for PLTP activity and parameters of body composition, such as body fat, BMI, and waist circumference (22,23,41). Also in the present study, both waist circumference and BMI were positively correlated with PLTP activity. In multivariate analysis, however, waist circumference was the better predictor. Increase in abdominal fat accumulation, as represented by increase in waist circumference, strongly relates to insulin resistance (42). Therefore, it is not surprising that patients with hypertriglyceridemia without diabetes have increased levels of PLTP activity as well (21). However, neither plasma glucose levels nor A1C were strong predictors for PLTP activity in the present study, even though glycemic control was suboptimal. Also, no sex-specific difference in PLTP activity or mass was found.

Mice with a genetic deficiency of PLTP have impaired hepatic secretion of apoB-containing particles, which is in favor of a role for PLTP in the biosynthetic pathway of VLDL by enabling donation of lipids to the nascent particles (14). In accordance with this mechanism, overexpression of human PLTP in transgenic mice results in elevated rates of hepatic VLDL secretion (43). Indeed, a number of clinical studies have reported the existence of a link between plasma apoB or LDL cholesterol and PLTP activity (20,41), but in the present study, we were unable to find evidence for this association. It has to be noted that we selected our patients on the presence of raised plasma triglycerides. As a result, we observed relatively small ranges in plasma apoB and cholesterol levels (Table 1), which could have obscured a relationship between PLTP activity and LDL cholesterol levels. Positive correlations with plasma triglycerides and cholesterol have been reported in a Finnish population study (44), but this could not be replicated in the present study, where correlations with triglycerides ($r = 0.10$, NS) and cholesterol ($r = 0.00$, NS) were only weak or absent.

Plasma apoE levels at baseline were associated with PLTP activity in both univariate and multivariate analyses. None of the other lipid variables or determinants of

FIG. 2. Relationship between the change in apoE (*y*-axis) and the change in PLTP activity (*x*-axis) during atorvastatin treatment. Spearman correlation coefficient $r_s = 0.595$, $P < 0.001$.

glucose homeostasis, like glucose levels and A1C, showed any significant contribution. PLTP mass, on the other hand, strongly positively correlated with plasma HDL cholesterol and apoAI and negatively with plasma triglycerides in univariate analysis. Multivariate analysis revealed that PLTP mass was predominantly explained by HDL cholesterol levels. Plasma PLTP is present in two forms: one form with little, if any, phospholipid transfer activity and another form with high activity. Both are associated with macromolecular complexes of different size (30,32). The inactive form is present on larger HDL particles, compared with the active form. The currently used PLTP mass assay has been extensively validated and is capable of analyzing both the catalytically active and inactive forms (45). Because the greater part of plasma PLTP is inactive and because inactive PLTP copurifies with apoAI (32), it can be appreciated that PLTP mass and apoAI, as well as HDL cholesterol, are related (21).

Atorvastatin treatment significantly reduced plasma apoE levels and plasma PLTP activity, whereas total PLTP mass was increased. Evidence for a possible role for apoE in PLTP homeostasis has been obtained in a number of different studies. The active form of PLTP copurifies with apoE, whereas the inactive form is associated with apoAI (32). In addition, active PLTP secreted from HepG2 cells coelutes with apoE but not with apoAI (46). Furthermore, apoE but not apoAI is able to convert inactive PLTP into the active form (34). In light of these and our present observations, we hypothesize that atorvastatin, via its lowering effect on apoE concentration mediated through elevation of hepatic LDL receptors, destabilizes the active form of PLTP. As a consequence, PLTP could be partly inactivated, resulting in lowering of PLTP activity. Finally, more inactive PLTP may have contributed to the observed elevation of plasma PLTP mass. In conclusion, the present study shows, for the first time, that a statin is able to decrease PLTP activity and supports our hypothesis that apoE may stabilize PLTP in vivo.

ACKNOWLEDGMENTS

The DALI study was supported by an unrestricted grant of Parke-Davis, the Netherlands.

The authors thank all the individuals who have contributed to the DALI study as patient, technician, or data manager. We acknowledge T. van Gent, Department of Cell Biology; Erasmus Medical Center, Rotterdam, and A. Zonneveld, Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, for the analyses of PLTP activity in the current study.

APPENDIX

The DALI Study Group. In alphabetical order: Erasmus Medical Center Rotterdam, Department of Internal Medicine: I. Berk-Planken, N. Hoogerbrugge, and H. Jansen; Erasmus University Rotterdam, Departments of Biochemistry and Clinical Chemistry: H. Jansen; Gaubius Laboratory TNO-KvL, Leiden: H.M.G. Princen; Leiden University Medical Center: M.V. Huisman and M.A. van de Ree; University Medical Center Utrecht, Julius Center for General Practice and Patient Oriented Research: R.P. Stolk and F.V. van Venrooij; University Medical Center Utrecht, Division of Internal Medicine: J.D. Banga, G.M. Dallinga-Thie, and F.V. van Venrooij.

REFERENCES

- Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 339:229–234, 1998
- Reaven GM: The insulin resistance syndrome. *Curr Atheroscler Rep* 5:364–371, 2003
- Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. *Circulation* 82:495–506, 1990
- Barter P: HDL: a recipe for longevity. *Atheroscler Suppl* 5:25–31, 2004
- Stein O, Stein Y: Lipid transfer proteins (LTP) and atherosclerosis. *Atherosclerosis* 178:217–230, 2005
- Albers JJ, Cheung MC: Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. *Curr Opin Lipidol* 15:255–260, 2004
- Rye KA, Barter PJ: Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor. *Biochim Biophys Acta* 875:429–438, 1986
- Jauhainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C: Human plasma phospholipid transfer protein causes high density lipoprotein conversion. *J Biol Chem* 268:4032–4036, 1993
- Van Haperen R, van Tol A, Vermeulen P, Jauhainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R: Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. *Arterioscler Thromb Vasc Biol* 20:1082–1088, 2000
- Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. *J Clin Invest* 103:907–914, 1999
- Van Tol A: Phospholipid transfer protein. *Curr Opin Lipidol* 13:135–139, 2002
- Qin SC, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, Jiang XC: Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. *J Lipid Res* 41:269–276, 2000
- Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, Fisher EA, Williams KJ: Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. *J Biol Chem* 280:18336–18340, 2005
- Jiang XC, Qin SC, Qiao CP, Kawano K, Lin M, Skold A, Xiao X, Tall AR: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. *Nat Med* 7:849–854, 2001
- Van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. *J Biol Chem* 277:48938–48943, 2002
- Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Sadeghi-Niaraki F, van Tol A: Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. *J Lipid Res* 45:805–811, 2004
- Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. *Arterioscler Thromb Vasc Biol* 23:1601–1607, 2003
- Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC: High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. *Arterioscler Thromb Vasc Biol* 23:1857–1862, 2003
- Riemens SC, van Tol A, Sluiter WJ, Dullaart RP: Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. *Diabetologia* 41:929–934, 1998
- Colhoun HM, Taskinen MR, Otvos JD, van den Berg P, O'Connor J, van Tol A: Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. *Diabetes* 51:3300–3305, 2002
- Jonkers LJ, Smelt AH, Hattori H, Scheek LM, van Gent T, de Man FH, Van der Laarse A, van Tol A: Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. *J Lipid Res* 44:1462–1469, 2003
- Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, van Tol A: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. *Eur J Clin Invest* 24:188–194, 1994
- Kaser S, Sandhofer A, Foger B, Ebenbichler CF, Igelseder B, Malaimare L,

- Paulweber B, Patsch JR: Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. *Diabetologia* 44:1111–1117, 2001
24. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G: ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. *J Lipid Res* 42:281–290, 2001
 25. Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ: Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. *J Lipid Res* 44:1113–1123, 2003
 26. Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, Kaye JA, Jin LW, Albers JJ: Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. *J Neurosci Res* 80:406–413, 2005
 27. Desrumaux C, Risold PY, Schroeder H, Deckert V, Masson D, Athias A, Laplanche H, Le GN, Blache D, Jiang XC, Tall AR, Desor D, Lagrost L: Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. *FASEB J* 19:296–297, 2005
 28. Gander R, Eller P, Kaser S, Theurl I, Walter D, Sauper T, Ritsch A, Patsch JR, Foger B: Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein. *J Lipid Res* 43:636–645, 2002
 29. Oka T, Kujiraoka T, Ito M, Nagano M, Ishihara M, Iwasaki T, Egashira T, Miller NE, Hattori H: Measurement of human plasma phospholipid transfer protein by sandwich ELISA. *Clin Chem* 46:1357–1364, 2000
 30. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, Miller NE, Metso J, Olkkonen VM, Ehnholm C, Jauhiainen M, Hattori H: Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. *J Lipid Res* 41:1651–1657, 2000
 31. Murdoch SJ, Wolfbauer G, Kennedy H, Marcovina SM, Carr MC, Albers JJ: Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. *J Lipid Res* 43:281–289, 2002
 32. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, Ehnholm C: Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). *J Biol Chem* 277:15413–15418, 2002
 33. Siggins S, Karkkainen M, Tenhunen J, Metso J, Tahvanainen E, Olkkonen VM, Jauhiainen M, Ehnholm C: Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. *J Lipid Res* 45:387–395, 2004
 34. Janis MT, Metso J, Lankinen H, Strandin T, Olkkonen VM, Rye KA, Jauhiainen M, Ehnholm C: Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. *Biochem Biophys Res Commun* 331:333–340, 2005
 35. Diabetes Atorvastin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. *Diabetes Care* 24:1335–1341, 2001
 36. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 23:S4–S19, 2000
 37. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. *Clin Chem* 18:499–502, 1972
 38. Speijer H, Groener JE, van Ramshorst E, van Tol A: Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. *Atherosclerosis* 90:159–168, 1991
 39. Damen J, Regts J, Scherphof G: Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins: dependence on cholesterol content and phospholipid composition. *Biochim Biophys Acta* 665:538–545, 1981
 40. Schneider M, Verges B, Klein A, Miller ER, Deckert V, Desrumaux C, Masson D, Gambert P, Brun JM, Fruchart-Najib J, Blache D, Witztum JL, Lagrost L: Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. *Diabetes* 53:2633–2639, 2004
 41. Cheung MC, Knopp RH, Retzlaff B, Kennedy H, Wolfbauer G, Albers JJ: Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. *Biochim Biophys Acta* 1587:53–59, 2002
 42. Poirier P, Lemieux I, Mauriege P, Dewailly E, Blanchet C, Bergeron J, Despres JP: Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. *Hypertension* 45:363–367, 2005
 43. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, van Tol A: Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. *J Lipid Res* 43:1875–1880, 2002
 44. Huuskonen J, Ekström M, Tahvanainen E, Vainio A, Metso J, Pussinen P, Ehnholm C, Olkkonen VM, Jauhiainen M: Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. *Atherosclerosis* 151:451–461, 2000
 45. Oka T, Yamashita S, Kujiraoka T, Ito M, Nagano M, Sagehashi Y, Egashira T, Nanjee MN, Hirano K, Miller NE, Matsuzawa Y, Hattori H: Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. *J Lipid Res* 43:1236–1243, 2002
 46. Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C: PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. *J Lipid Res* 44:1698–1704, 2003